4.5 Letter

A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL

Journal

BLOOD CANCER JOURNAL
Volume 11, Issue 4, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41408-021-00465-9

Keywords

-

Funding

  1. National Key R&D Program of China [2019YFA0110200]
  2. Tianjin Science Funds for Distinguished Young Scholars [17JCJQJC45800]
  3. CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-003]
  4. Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2018PT32034]
  5. National Natural Science Foundation of China [81870090]

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available